Press releases

‍Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies.

VERAXA Biotech and Navigo Proteins Initiate Research Collaboration to Establish Pre-Targeting Strategies for Novel Affilin Radio Conjugates

The agreement brings together Navigo Protein’s Affilin® platform with VERAXA’s proprietary click chemistry platform and conjugation expertise

VERAXA Biotech Launches New BiTAC Platform to Develop Breakthrough Antibody Therapies with Unprecedented Safety Features

BiTACs benefit from novel architecture with combinatorial-gated design for cancer targeting and built-in safety features

VERAXA Biotech Announces Formation of Clinical Advisory Board to Support Expansion of Proprietary Pipeline in Oncology

Board adds profound clinical expertise in oncology as well as expertise across multiple antibody-based therapeutic modalities to VERAXA

VERAXA Biotech Signs Exclusive License Agreement with Cherry Biolabs to Expedite the Development of New Technology Platforms

New IP combined with VERAXA’s deep ADC and antibody expertise to give rise to new therapeutic strategies with unique safety features

VERAXA Biotech Accelerates Transition to Clinical-Stage Development Company with Synimmune Acquisition

The addition of a clinical-stage FLT3-targeting cancer antibody program acts as steppingstone for further pipeline and technology expansion.

Torsten Buergermeister Joins VERAXA Biotech GmbH as Chief Financial Officer

The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.

VERAXA Biotech GmbH Appoints Dr. Lars Hufnagel to Chief Technical Officer

Lars Hufnagel will be responsible for advancing VERAXA’s antibody screening and ADC technologies by further developing its droplet-based microfluidic screening technology.

VERAXA Biotech and Indivumed Cooperate on the Development of Precision Oncology Antibody Drugs

VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development